Steven James Brandt

US Patent:

6436936, Aug 20, 2002

Filed:

Jul 22, 1998

Appl. No.:

09/121029

Inventors:

James W. Young - Palo Alto CA
Steven Brandt - Marlborough MA

Assignee:

Sepracor Inc.

International Classification:

A61K 31495

US Classification:

514249

Abstract:

Methods and compositions are disclosed utilizing the optically pure (+) isomer of zopiclone. This compound is a potent drug for the treatment of sleep disorders, such as insomnia, and convulsive disorders, such as epilepsy. Similarly, these novel compositions and methods are useful for the treatment of sleep disorders and convulsive disorders while avoiding the concomitant liability of adverse effects associated with the racemic mixture of zopiclone. The optically pure (+) isomer of zopiclone is also useful for treating disorders that are affected by the binding of agonists to central nervous system or peripheral benzodiazepine receptors. Also described are methods and compositions for treating disorders that are affected by binding of agonists to central nervous system or peripheral benzodiazepine receptors while avoiding the adverse effects associated with the administration of the racemic mixture of zopiclone.

US Patent:

57863571, Jul 28, 1998

Filed:

Aug 1, 1994

Appl. No.:

8/283497

Inventors:

James W. Young - Palo Alto CA
Steven Brandt - Marlborough MA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K 31495
A61K 3150

US Classification:

514249

Abstract:

Methods and compositions are disclosed utilizing the optically pure (+) isomer of zopiclone. This compound is a potent drug for the treatment of sleep disorders, such as insomnia, and convulsive disorders, such as epilepsy. Similarly, these novel compositions and methods are useful for the treatment of sleep disorders and convulsive disorders while avoiding the concomitant liability of adverse effects associated with the racemic mixture of zopiclone. The optically pure (+) isomer of zopiclone is also useful for treating disorders that are affected by the binding of agonists to central nervous system or peripheral benzodiazepine receptors. Also described are methods and compositions for treating disorders that are affected by binding of agonists to central nervous system or peripheral benzodiazepine receptors while avoiding the adverse effects associated with the administration of the racemic mixture of zopiclone.